Abstract
Background and objective: Sleep architecture changes with age, both in terms of efficiency and total duration of sleep. Hypnotic benzodiazepines promote rapid onset of sleep, uninterrupted sleep and longer duration of sleep in the absence of carryover sedation the following morning; therefore, these may be appropriate for use in older patients. This study was performed to evaluate the efficacy and safety of lormetazepam in elderly patients with primary insomnia when used in association with sleep hygiene training (SHT). The impact of restored sleep on daily sleepiness was also investigated.
Patients and methods: In this open-label study, 30 elderly outpatients with insomnia were randomised to receive 2 weeks of treatment with lormetazepam 0.5mg + SHT or SHT alone, followed by a 1-week observation period. Details on sleep latency, number of awakenings and freshness on awakening were recorded by patients in a daily sleep diary. The Epworth Sleepiness Scale (ESS) and Stanford Sleepiness Scale (SSS) were used to measure daily sleepiness.
Results: Addition of lormetazepam to SHT improved all sleep parameters measured compared with SHT alone. Mean duration of sleep improved significantly from baseline (mean rank = 1.00) in the lormetazepam + SHT group after 2 weeks of treatment (mean rank 2.87; Friedmann test = 27.448; p < 0.001), but declined significantly in the group receiving SHT alone (from mean rank 2.33 to 1.57; Friedmann test = 6.465; p < 0.05). Mean duration of sleep increased by approximately 150 minutes each night in the lormetazepam + SHT group but decreased by more than 30 minutes in the SHT-only group. Improvement in sleep quality from baseline was statistically significant only in the lormetazepam + SHT group: for both deepness of sleep and the perception of awakening refreshed, mean scores increased from approximately 3 at baseline to approximately 8 (on a scale of 1–10) after 2 weeks in this group. Sleep latency also decreased significantly in the lormetazepam + SHT group: after 2 weeks, on average patients were awakening less than once per night. SSS and ESS scores also improved significantly in the lormetazepam + SHT group; in contrast, in the SHT-only group, the mean ESS score worsened significantly from baseline and the mean SSS score remained relatively constant. No rebound insomnia was reported during follow-up in patients in the lormetazepam group. Vital signs did not change from baseline and no adverse events were reported for either group.
Conclusion: Management of insomnia in the elderly appears to have a better outcome when pharmacotherapy is combined with SHT rather than SHT alone. The earlier improvement in sleep quality with lormetazepam when used in combination with a sleep training programme may help to maintain adherence to treatment.
Similar content being viewed by others
References
Asplund R. Sleep disorders in the elderly. Drugs Aging 1999 Feb; 14(2): 91–103
Buysse DJ. Insomnia, depression and ageing: assessing sleep and mood interactions in older adults. Geriatrics 2004 Feb; 59(2): 47–51
Goldstein MZ. Practical geriatrics: insomnia in late life. Psychiatr Serv 2001 Dec; 5(12): 1573–5
Piani A, Brotini S, Dolso P, et al. Sleep disturbances in the elderly: a subjective evaluation over 65. Arch Gerontol Geriatr 2004; 9 Suppl.: 325–31
Moller HJ, Barbera J, Kayumov L, et al. Psychiatric aspects of late-life insomnia. Sleep Med Rev 2004 Feb; 8(1): 31–45
Kryger M, Monjan A, Bliwise D, et al. Sleep, health and ageing: bridging the gap between science and clinical practice. Geriatrics 2004 Jan; 59(1): 24–6, 29-30
Pallesen S, Nordhus IH, Kvale G, et al. Psychological characteristics of elderly insomniacs. Scand J Psychol 2002 Dec; 43(5): 425–32
Morgan K. Daytime activity and risk factors for late-life insomnia. J Sleep Res 2003 Sep; 12(3): 231–8
Ancoli-Israel S, Cooke JR. Prevalence and comorbidity of insomnia and effect on functioning in elderly populations. J Am Geriatr Soc 2005 Jul; 53(7 Suppl.): S264–71
Montgomery P, Dennis J. A systematic review of non-pharmacological therapies for sleeping problems in later life. Sleep Med Rev 2004 Feb; 8(1): 47–62
Irwin MR, Cole JC, Nicassio PM. Comparative meta-analysis of behavioral interventions for insomnia and their efficacy in middle-aged adults and in older adults 55+ years of age. Health Psychol 2006 Jan; 25(1): 3–14
Morin CM, Culbert JP, Schwartz SM. Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy. Am J Psychiatry 1994 Aug; 151(8): 1172–80
Murtagh DR, Greenwood KM. Identifying effective psychological treatments for insomnia: a meta-analysis. J Consult Clin Psychol 1995 Feb; 63(1): 79–89
Montgomery P, Dennis J. Cognitive behavioural interventions for sleep problems in adults aged 60+. Cochrane Database Syst Rev 2003; 1: CD003161
Morin CM, Colecchi C, Stone J, et al. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA 1999 Mar 17; 281(11): 991–9
Sivertsen B, Omvik S, Pallesen S, et al. Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial. JAMA 2006 Jun 28; 295(24): 2851–8
Richards HH, Valle-Jones CJ. A double-blind comparison of two lormetazepam doses in elderly insomniacs. Curr Med Res Opin 1988; 11(1): 48–55
de las Cuevas C, Sanz E, de la Fuente J. Benzodiazepines: more ‘behavioural’ addiction than dependence. Psychopharmacology (Berl) 2003 May; 167(3): 297–303
Luscombe DK. Lormetazepam plasma concentrations in volunteers following sublingual and oral dosing. Psychopharmacol 1984 Suppl.; 1: 99–104
Deijen JB, Heemstra ML, Orlebeke JF. Residual effects of lormetazepam on mood and performance in healthy elderly volunteers. Eur J Clin Pharmacol 1991; 40(3): 267–71
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV TR). Arlington: American Psychiatric Association, 2000
Folstein M, Folstein S, McHugh P. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–98
Michael B. First, MD, Robert L, et al. Clinical interview for DSM-IV® axis I disorders (SCID-I), clinician version. Arlington (VA): American Psychiatric Publishing Incorporated, 1997
Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991 Dec; 14(6): 540–5
Hoddes E, Zarcone V, Smythe H, et al. Quantification of sleepiness: a new approach. Psychophysiology 1973 Jul; 10(4): 431–6
Zarcone VP. Sleep hygiene. In: Kryger MH, Roth T, Dement WC, editors.lPrinciples and practice of sleep medicine.Philadelphia (PA): Saunders, 1994: 542–6
Wheatley D. Prescribing short-acting hypnosedatives: current recommendations from a safety perspective. Drug Saf 1992 Mar–Apr; 7(2): 106–15
Humpel M, Nieuweboer B, Milius W, et al. Kinetics and biotransformation of lormetazepam. II: Radioimmunologic determinations in plasma and urine of young and elderly subjects: first-pass effect.Clin Pharmacol Ther 1980 Nov; 28(5): 673–9
Cricco M, Simonsick EM, Foley DJ. The impact of insomnia on cognitive functioning in older adults. J Am Geriatr Soc 2001 Sep; 49(9): 1185–9
Rosen RC, Lewin DS, Goldberg L, et al. Psycho-physiological insomnia: combined effects of pharmacotherapy and relaxation-based treatments. Sleep Med 2000 Oct; 1(1): 279–88
Acknowledgements
The authors would like to thank Schering-SpA for an educational grant provided to assist with the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vanna, M.D., Rubiera, M., Onor, M.L. et al. Role of Lormetazepam in the Treatment of Insomnia in the Elderly. Clin. Drug Investig. 27, 325–332 (2007). https://doi.org/10.2165/00044011-200727050-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00044011-200727050-00003